Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

OMEPRAZOLE vs ONASEMNOGENE ABEPARVOVEC-XIOI: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

OMEPRAZOLE vs ONASEMNOGENE ABEPARVOVEC-XIOI: Safety Overview

Metric OMEPRAZOLE ONASEMNOGENE ABEPARVOVEC-XIOI
Total FAERS Reports 87,111 2,098
Deaths Reported 8,515 142
Death Rate 9.8% 6.8%
Hospitalizations 19,847 664
Average Patient Age 58.7 yrs 1.4 yrs
% Female Patients 58.9% 52.2%
FDA Approval Date Apr 17, 2009 N/A
Manufacturer Cipla USA Inc. Novartis Gene Therapies, Inc.
Route ORAL N/A
Marketing Status Discontinued N/A